The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study
- PMID: 25193800
- DOI: 10.1016/j.resuscitation.2014.08.017
The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study
Abstract
Aim: The whole body ischaemia-reperfusion after cardiac arrest (CA) induces a systemic inflammation-reperfusion response. The expression of urokinase plasminogen activator receptor (uPAR) is known to be induced after hypoxia and increased levels of soluble form suPAR have been measured after hypoxia and ischaemia. Our aim was to evaluate, whether ischaemia/reperfusion injury after out-of-hospital cardiac arrest (OHCA) increases suPAR concentrations in serum and to evaluate the prognostic value of suPAR regarding 90-day mortality and 12-month neurological outcome.
Methods: This is a pre-determined substudy of prospective FINNRESUSCI study. Total of 287 patients treated in the intensive care units after OHCA and with consent from the next-of-kin and serum samples between baseline and day 4 were included. Outcome and neurological outcome were evaluated according the Pittsburgh Cerebral Performance Categories (CPC). Kaplan-Meier survival curves, areas under receiver operational characteristics curves and positive likelihood ratios for mortality and poor neurological outcome were calculated.
Results: Non-survivors had higher levels of suPAR after OHCA. Kaplan-Meier survival curves indicated high 90-day mortality in the highest concentration quintiles. LR+ for 1-year CPC 3-5 was 1.8-2.7 for the whole patient cohort and in shockable rhythms 2.0-2.4. In therapeutic hypothermia prognostic value remained.
Conclusions: We found that high SuPAR concentrations were associated with poor outcome in patients with OHCA admitted to critical care. However, suPAR alone had inadequate predictive value for poor outcome and did not associate with 12-month neurological outcome.
Keywords: Biomarkers; OHCA; Out-of-hospital cardiac arrest; Prognostication after cardiac arrest; Resuscitation; Soluble urokinase plasminogen activator receptor (suPAR).
Copyright © 2014. Published by Elsevier Ireland Ltd.
Similar articles
-
Soluble Urokinase-Type Plasminogen Activator Receptor in Comatose Survivors After Out-of-Hospital Cardiac Arrest Treated with Targeted Temperature Management.Ther Hypothermia Temp Manag. 2024 Dec;14(4):243-251. doi: 10.1089/ther.2023.0039. Epub 2023 Nov 1. Ther Hypothermia Temp Manag. 2024. PMID: 37910781 Clinical Trial.
-
Admission interleukin-6 is associated with post resuscitation organ dysfunction and predicts long-term neurological outcome after out-of-hospital ventricular fibrillation.Resuscitation. 2014 Nov;85(11):1573-9. doi: 10.1016/j.resuscitation.2014.08.036. Epub 2014 Sep 17. Resuscitation. 2014. PMID: 25238742
-
Short- and long-term outcome in elderly patients after out-of-hospital cardiac arrest: a cohort study.Crit Care Med. 2014 Nov;42(11):2350-7. doi: 10.1097/CCM.0000000000000512. Crit Care Med. 2014. PMID: 25054671
-
Cardiac catheterization is associated with superior outcomes for survivors of out of hospital cardiac arrest: review and meta-analysis.Resuscitation. 2014 Nov;85(11):1533-40. doi: 10.1016/j.resuscitation.2014.08.025. Epub 2014 Sep 4. Resuscitation. 2014. PMID: 25195073 Review.
-
Soluble urokinase plasminogen activator receptor--a valuable biomarker in systemic lupus erythematosus?Clin Chim Acta. 2015 Apr 15;444:234-41. doi: 10.1016/j.cca.2015.02.031. Epub 2015 Feb 19. Clin Chim Acta. 2015. PMID: 25704300 Review.
Cited by
-
[Biomarkers after resuscitation : Relevance in daily clinical practice for prognosis estimation and definition of therapeutic goals].Med Klin Intensivmed Notfmed. 2019 May;114(4):313-318. doi: 10.1007/s00063-019-0571-x. Epub 2019 Mar 28. Med Klin Intensivmed Notfmed. 2019. PMID: 30923852 Review. German.
-
Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris.Exp Dermatol. 2022 Sep;31(9):1341-1351. doi: 10.1111/exd.14582. Epub 2022 May 16. Exp Dermatol. 2022. PMID: 35474520 Free PMC article.
-
Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease.J Clin Med Res. 2021 Mar;13(3):133-142. doi: 10.14740/jocmr4459. Epub 2021 Mar 19. J Clin Med Res. 2021. PMID: 33854652 Free PMC article. Review.
-
Soluble Urokinase-Type Plasminogen Activator Receptor in Comatose Survivors After Out-of-Hospital Cardiac Arrest Treated with Targeted Temperature Management.Ther Hypothermia Temp Manag. 2024 Dec;14(4):243-251. doi: 10.1089/ther.2023.0039. Epub 2023 Nov 1. Ther Hypothermia Temp Manag. 2024. PMID: 37910781 Clinical Trial.
-
Soluble urokinase plasminogen activation receptor--An emerging new biomarker of cardiovascular disease and critical illness.Ann Card Anaesth. 2016 Apr-Jun;19(2):214-6. doi: 10.4103/0971-9784.179588. Ann Card Anaesth. 2016. PMID: 27052059 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical